SARS News and Research

RSS

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

A recent report published in the New England Journal of Medicine has revealed that the COVID-19 vaccine developed by Moderna, Inc, USA, is capable of inducing robust and durable antibody responses for at least six months post-vaccination.

8 Apr 2021

Thermo Fisher Scientific launches in-air SARS-CoV-2 surveillance solution

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the Thermo Scientific AerosolSense Sampler, a new surveillance solution designed to deliver fast and highly reliable insight into the presence of in-air pathogens, including SARS-CoV-2.

From Thermo Fisher Scientific – Environmental and Process Monitoring Instruments 8 Apr 2021

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

8 Apr 2021

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

A new preprint research paper posted to the bioRxiv server reports on the ability of a set of neutralizing mouse antibodies to protect mice against multiple lineages of SARS-CoV-2.

8 Apr 2021

Landmark discovery may lead to safe, effective antiviral drugs against COVID-19

The COVID-19 vaccines currently rolling out are providing hope that the spread of the disease can be halted. But infection rates are still high, and for those who contract COVID-19, the search for effective treatments remains important.

8 Apr 2021

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

The gut is a well-established route of infection and target for viral damage by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) symptoms.

8 Apr 2021

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

Mobility tracking using cell phone data showing greater movement of people is a strong predictor of increased rates of COVID-19, according to new data in CMAJ (Canadian Medical Association Journal)

8 Apr 2021

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

Eight months after mild COVID-19, one in ten people still has at least one moderate to severe symptom that is perceived as having a negative impact on their work, social or home life. The most common long-term symptoms are a loss of smell and taste and fatigue.

8 Apr 2021

The interaction between blood clotting and SARS-CoV-2 infection

Coagulopathy - a condition in which the blood's ability to clot is impaired, is recognized as a significant aspect of morbidity in COVID-19 patients. In a recent study, Prof Lewis Cantley and a team of researchers explored the role of coagulation factors in the SARS-CoV-2 infection. Their recent study is posted on the bioRxiv server.

7 Apr 2021

Real-world proof Pfizer and Moderna mRNA vaccines prevent SARS-CoV-2 infection

A new Morbidity and Mortality Weekly Report published by the U.S. Centers for Disease Control and Prevention (CDC) states that mRNA COVID-19 vaccines are highly effective in preventing SARS-CoV-2 infection in the real world. The report is based on a CDC study where it routinely tested prospective cohorts of health care professionals, first responders, and essential and frontline workers for SARS-CoV-2 infections.

7 Apr 2021

Bispecific antibodies neutralize SARS-CoV-2 and its variants

A new bioRxiv preprint study led by Joshua Tan from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, involves generating bispecific antibodies using a new method cross-linking the antibodies with adjacent spike proteins using dual N-terminal domain/receptor binding domain specificity.

7 Apr 2021

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

Makdasi et al. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants. bioRxiv, 2021. doi: https://doi.org/10.1101/2021.04.01.438035, https://www.biorxiv.org/content/10.1101/2021.04.01.438035v2

7 Apr 2021

COVID-19 antibodies persist in breast milk for months following mother’s vaccination

Nursing mothers who receive a COVID-19 vaccine may pass protective antibodies to their babies through breast milk for at least 80 days following vaccination, suggests new research from Washington University School of Medicine in St. Louis.

7 Apr 2021

Michigan Medicine to kick off first national study on allergic reactions to COVID-19 vaccines

In a carefully controlled study, Michigan Medicine researchers will kick off the first national trial to study allergic reactions to the COVID-19 mRNA vaccines.

7 Apr 2021

NIH-funded clinical trial begins study of systemic allergic reactions to COVID-19 vaccines

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines.

7 Apr 2021

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

A team of scientists from the University of California Santa Cruz, USA, recently identified a novel variant (B.1.x) of SARS-CoV-2 that might be circulating in at least 20 US states and six countries globally.

7 Apr 2021

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

A promising new study reports on the high neutralizing efficacy of a polyclonal swine antibody against SARS-CoV-2, the pathogen responsible for the novel COVID-19. By demonstrating the ability of this antibody to neutralize all currently circulating viral variants, the study suggests that it is ideal for development as a new and very effective therapy for COVID-19.

7 Apr 2021

Which SARS-CoV-2 spike mutants can evade T cell immunity?

A new study reports the capability of a new variant of the virus to escape specific cellular immunity, while possessing a higher binding affinity to the host cell binding receptor, the angiotensin-converting enzyme 2 (ACE2).

7 Apr 2021

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

A new study describes the use of a single dose of vaccine based on the viral protein called the receptor-binding domain (RBD) to elicit powerful neutralizing activity against both the Wuhan strain and the most concerning VOC called the South African (SA) strain.

7 Apr 2021

Global secretive governments are bypassing rules during COVID-19 pandemic

From Brazil to the Philippines, secretive governments across the world are responding to the COVID-19 pandemic by covering up data and bypassing public procurement rules, undermining trust in health systems, fuelling anti-vaxxers and putting immunisation campaigns at risk.

7 Apr 2021

SARS News and Research

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

Thermo Fisher Scientific launches in-air SARS-CoV-2 surveillance solution

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

Mouse monoclonal antibodies protect against SARS-CoV-2 wildtype, UK and South African variants

Landmark discovery may lead to safe, effective antiviral drugs against COVID-19

Leaky gut and microbial dysbiosis could contribute to cytokine storm in severely ill COVID-19 cases

Smartphone mobility tracking strongly predicts COVID-19 outbreaks

Study: 1 in 10 people still has moderate to severe symptoms after mild COVID-19

The interaction between blood clotting and SARS-CoV-2 infection

Real-world proof Pfizer and Moderna mRNA vaccines prevent SARS-CoV-2 infection

Bispecific antibodies neutralize SARS-CoV-2 and its variants

Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants

COVID-19 antibodies persist in breast milk for months following mother’s vaccination

Michigan Medicine to kick off first national study on allergic reactions to COVID-19 vaccines

NIH-funded clinical trial begins study of systemic allergic reactions to COVID-19 vaccines

Researchers identify novel SARS-CoV-2 variant unregistered on genomic sequence databases

Novel polyclonal antibody XAV-19 efficiently neutralizes UK and South African SARS-CoV-2 variants

Which SARS-CoV-2 spike mutants can evade T cell immunity?

Enhanced neutralization of SARS-CoV-2 South African variant with heterologous adjuvant vaccine candidate

Global secretive governments are bypassing rules during COVID-19 pandemic

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News